Cardlytics Reports Q4 Revenue Beat, Issues Weak Q1 Guidance Amidst Bank of America Campaign Conclusion
CDLX is trading near its 52-week low of $0.751 (7.9% above the low).
Summary
Cardlytics reported better-than-expected Q4 2025 financial results, including a revenue beat and improved profitability, but issued significantly weaker Q1 2026 guidance, citing the conclusion of its Bank of America campaigns.
Key Events · Earnings and Guidance · CDLX
-
Q4 2025 Revenue Beat
Reported total revenue of $56.1 million for Q4 2025, exceeding analyst estimates of $54.45 million, despite a 24.2% year-over-year decrease.
-
Improved Q4 Profitability
Net loss significantly narrowed to $(8.3) million from $(15.6) million in Q4 2024. Adjusted EBITDA increased 33.4% year-over-year to $8.5 million, and Free Cash Flow turned positive at $10.5 million.
-
Weak Q1 2026 Guidance
Forecasts substantial year-over-year declines for Q1 2026, with Billings expected between $57.5M - $63.5M (down 41-35%) and Revenue between $35.0M - $40.0M (down 43-35%). The company also projects a return to negative Adjusted EBITDA of $(7.5) million to $(3.5) million.
-
Strategic Headwinds from Partner Loss
Management explicitly noted an anticipated decrease in Monthly Qualified Users (MQUs) following the conclusion of its Bank of America campaigns in January, impacting future performance.
Analysis · CDLX · Technology
Cardlytics delivered a strong fourth quarter, surpassing revenue expectations and showing significant improvements in net loss, Adjusted EBITDA, and free cash flow. This indicates effective cost management and operational efficiency during the period. However, the positive Q4 results are overshadowed by a very challenging outlook for Q1 2026, with guidance pointing to substantial year-over-year declines in key financial metrics and a projected return to Adjusted EBITDA losses. The company attributes these headwinds to the conclusion of its Bank of America campaigns, which will lead to a decrease in Monthly Qualified Users (MQUs). This filing highlights a critical transition period for Cardlytics as it navigates the loss of a major partner and focuses on achieving "self-sustainability" through disciplined execution and cost management. Investors should monitor the company's ability to offset the impact of lost MQUs and stabilize its revenue base in the coming quarters.
At the time of this filing, CDLX was trading at $0.81 on NASDAQ in the Technology sector, with a market capitalization of approximately $48.7M. The 52-week trading range was $0.75 to $3.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.